KNTE Stock: Kinnate Biopharma Inc. Stock Price, Analysis & Insights

Get live KNTE stock price $2.65, comprehensive Kinnate Biopharma Inc. stock analysis, charts, news, and expert forecast. Real-time KNTE stock data and investment insights.

Quick links:Financial Metrics•Earnings•Analyst Forecasts•Financials•Technicals

2.65

0.38%Today

KNTE • Kinnate Biopharma Inc. • NASDAQ Global Select • Healthcare

Market Cap

124.99M

Volume

2.12M

52W High

7.18

52W Low

1.04

Loading chart data...

Investment Score

Annual (latest period)

Unavailable

A systematic tri-factor framework that integrates valuation, business quality, and market momentum into one investment signal. This helps investors triage opportunities faster, while surfacing risk regimes that may require tighter position sizing or deeper due diligence.

Score unavailable for this asset.

View full dashboardUnlock quarterlyFaster signals · Pro+

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Kinnate Biopharma Inc. is a U.S.-based biopharmaceutical company primarily focused on identifying and advancing small-molecule drugs that target kinase enzymes to treat cancers defined by specific genetic markers. The company's product pipeline inclu...

Contact Information

Website: https://www.kinnate.com
Address: 103 Montgomery Street
Country: US

Investment Analysis & Business Insights

Healthcare

Biotechnology

Investment Highlights

✓ Strong presence in the Healthcare sector with established market position

✓ Higher growth potential with elevated volatility (Beta: 1.34)

Important Investment Considerations

⚠All investments carry risk, including potential loss of principal for Kinnate Biopharma Inc. shareholders
⚠Market volatility can significantly impact stock price, especially for smaller companies
⚠Sector-specific risks in Healthcare may affect company performance
⚠Past performance does not guarantee future results for Kinnate Biopharma Inc.
⚠Investors should consider how Kinnate Biopharma Inc. fits within their overall portfolio allocation
⚠Valuation metrics suggest potential, but require fundamental analysis

Market Cap

124.99M

P/E Ratio (TTM)

-0.95

Beta

1.34

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

Related Stocks

Compare KNTE with peer companies:

Aadi Bioscience, Inc. (AADI)

Price: $2.05
Market cap: 94.89M

aTyr Pharma, Inc. (ATYR)

Price: $0.46
Market cap: 45.38M

Decibel Therapeutics, Inc. (DBTX)

Price: $4.91
Market cap: 123.37M

Graybug Vision, Inc. (GRAY)

Price: $5.50
Market cap: 120.98M

NGM Biopharmaceuticals, Inc. (NGM)

Price: $1.54
Market cap: 128.53M

Pardes Biosciences, Inc. (PRDS)

Price: $2.18
Market cap: 135.19M

Paratek Pharmaceuticals, Inc. (PRTK)

Price: $2.23
Market cap: 127.83M

RVL Pharmaceuticals plc (RVLP)

Price: $0.03
Market cap: 3.14M

Sesen Bio, Inc. (SESN)

Price: $0.63
Market cap: 127.96M

Tourmaline Bio, Inc. (TRML)

Price: $47.98
Market cap: 1.23B

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.